There were 1,421 press releases posted in the last 24 hours and 314,805 in the last 365 days.
– AVT001 met its primary endpoints (safety) and demonstrated a strong efficacy signal at the primary readout of its phase 1/2 study for Type 1 Diabetes
Emmie Fan
Avotres Inc.
+1 973-487-6972
email us here
You just read:
EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™, tries to define some of the boundaries that are reasonable in today’s world. Please see our Editorial Guidelines for more information.
Follow EIN Presswire
© 1995-2022 Newsmatics Inc. dba EIN Presswire
All Right Reserved.